<DOC>
	<DOCNO>NCT01998828</DOCNO>
	<brief_summary>This open-label study determine safety efficacy momelotinib participant either polycythemia vera ( PV ) essential thrombocythemia ( ET ) yet receive treatment Janus kinase ( JAK ) inhibitor .</brief_summary>
	<brief_title>Safety Efficacy Momelotinib Subjects With Polycythemia Vera Essential Thrombocythemia</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosis either PV ET define 2008 World Health Organization ( WHO ) Diagnostic Criteria Requires treatment PV ET , opinion study investigator Intolerant , resistant , refuse current available treatment PV ET Direct bilirubin ≤ 2.0 x upper limit normal range ( ULN ) Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 x ULN Calculated creatinine clearance ( CrCl ) ≥ 45 mL/min Life expectancy &gt; 24 week Male subject female subject childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Females nursing must agree discontinue nurse first dose study drug Able comprehend willing sign inform consent form Prior splenectomy Uncontrolled intercurrent illness , per protocol Known positive status human immunodeficiency virus ( HIV ) Chronic active acute viral hepatitis A , B , C infection , hepatitis B C carrier Myeloproliferative neoplasmdirected therapy , aspirin , hydroxyurea , anagrelide , and/or phlebotomy , within 21 day prior first dose study drug Anagrelide within 7 day prior first dose study drug Presence peripheral neuropathy ≥ Grade 2 Unwilling unable take oral medication Prior use JAK1 JAK2 inhibitor Use strong CYP3A4 inducer within 1 week prior first dose study drug QTc interval &gt; 450 msec , unless attribute bundle branch block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Polycythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Thrombocytosis</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
</DOC>